PROGRAM LEADERS AND PLAN Sample Clauses

PROGRAM LEADERS AND PLAN. Caliper and Amgen shall each designate a program leader. The program leaders shall jointly coordinate the activities carried out under this Agreement and monitor the progress of such activities on a periodic BASIS. From time to time, the program leaders shall mutually prepare and update a program plan describing (i) goals in terms of milestones and deliverables, (ii) the tasks and budget for Amgen support to be provided by Caliper personnel under Section 2.3, and (iii) such other matters as the program leaders may agree upon. The plan for 1999 is attached as Exhibit A (which shall be amended or modified only by mutual agreement of the parties). Plans for each subsequent year shall be mutually agreed by the parties not later than thirty (30) days prior to each such year (and thereafter shall be amended or modified only by mutual agreement of the parties). The dates set forth on the program plan for completion of tasks shall be good faith projections provided by Caliper and agreed to by Amgen. Caliper shall apply commercially reasonable efforts to achieve such objectives by such date and at all times thereafter until the objectives are achieved. [ * ] days prior to the end of each quarter, Caliper shall notify Amgen of its ability or inability to achieve that quarter's objectives within [ * ] days of the end of the quarter. If Caliper notifies Amgen that it is unable to satisfy that quarter's objectives within [ * ] days after the end of the quarter, or Caliper otherwise fails to satisfy such objectives within [ * ] days after the end of the quarter, then [ * ]. If Caliper fails to deliver within [ * ] days after the end of the [ * ] quarter of [ * ] the Multi Sipper Instrument scheduled to be delivered that quarter, then, in addition to the foregoing, Amgen's subscription under the TAP for 1999 shall automatically extend until [ * ] days following Amgen's purchase and receipt of the same or its written notice to Caliper of its election not to purchase the same (which purchase or notice shall occur not later than [ * ] days after Caliper notifies Amgen that such Multi Sipper Instrument is available for purchase). If Amgen elects to renew its subscription for 2000 (which election must be made prior to the expiration of the extended term of the 1999 subscription described in the foregoing sentence), then it must pay to Caliper the full year 2000 subscription fee of [ * ] prior to the expiration of the extended term of the 1999 subscription.
Sample 1Sample 2
AutoNDA by SimpleDocs
PROGRAM LEADERS AND PLAN. Caliper and Lilly shall each designate a TAP leader (each, a "Program Leader") who shall jointly coordinate the activities carried out under this Agreement and monitor the progress of such activities on a periodic basis. The initial Program Leader of Lilly shall be Jeff X. Xxxxxxx, Xx.D., and the initial Program Leader of Caliper shall be Stevxx X. Xxxxxxxx, Xx.D. From time to time, the Program Leaders shall jointly prepare and update a program plan (the "Program Plan") describing Lilly's goals as a Participant, the tasks for Lilly support to be provided by Caliper personnel under Section 2.3, and such other matters as the Program Leaders determine to be appropriate. The initial Program Plan is attached hereto as Exhibit A. Either party, in its sole discretion, may change its Program Leader by delivering written notice of the name and qualifications of the proposed successor Program Leader to the other party. If the other party questions the qualifications of the proposed successor, then the parties shall consult with one another in good faith for the purpose of resolving any issues. In the event of a change in Program Leader, a reasonable transition period shall be [ * ] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION PURSUANT TO RULE 406 OF THE SECURITIES ACT OF 1933, AS AMENDED.
Sample 1

Related to PROGRAM LEADERS AND PLAN

  • Collaboration Management Promptly after the Effective Date, each Party will appoint a person who will oversee day-to-day contact between the Parties for all matters related to the management of the Collaboration Activities in between meetings of the JSC and will have such other responsibilities as the Parties may agree in writing after the Effective Date. One person will be designated by Merck (the “Merck Program Director”) and one person will be designated by Moderna (the “Moderna Program Director,”) together will be the “Program Directors”. Each Party may replace its Program Director at any time by notice in writing to the other Party. Any Program Director may designate a substitute to temporarily perform the functions of that Program Director by written notice to the other Party. The initial Program Directors will be: For Moderna: [***] For Merck: [***]

  • Commercialization Plan On a Product by Product basis, not later than sixty (60) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory, the MSC shall prepare and approve a rolling multiyear (not less than three (3) years) plan for Commercializing such Product in the Copromotion Territory (the "Copromotion Territory Commercialization Plan"), which plan includes a comprehensive market development, marketing, sales, supply and distribution strategy for such Product in the Copromotion Territory. The Copromotion Territory Commercialization Plan shall be updated by the MSC at least once each calendar year such that it addresses no less than the three (3) upcoming years. Not later than thirty (30) days after the filing of the first application for Regulatory Approval of a Product in the Copromotion Territory and thereafter on or before September 30 of each calendar year, the MSC shall prepare an annual commercialization plan and budget (the "Annual Commercialization Plan and Budget"), which plan is based on the then current Copromotion Territory Commercialization Plan and includes a comprehensive market development, marketing, sales, supply and distribution strategy, including an overall budget for anticipated marketing, promotion and sales efforts in the upcoming calendar year (the first such Annual Development Plan and Budget shall cover the remainder of the calendar year in which such Product is anticipated to be approved plus the first full calendar year thereafter). The Annual Commercialization Plan and Budget will specify which Target Markets and distribution channels each Party shall devote its respective Promotion efforts towards, the personnel and other resources to be devoted by each Party to such efforts, the number and positioning of Details to be performed by each Party, as well as market and sales forecasts and related operating expenses, for the Product in each country of the Copromotion Territory, and budgets for projected Pre-Marketing Expenses, Sales and Marketing Expenses and Post-Approval Research and Regulatory Expenses. In preparing and updating the Copromotion Territory Commercialization Plan and each Annual Commercialization Plan and Budget, the MSC will take into consideration factors such as market conditions, regulatory issues and competition.

  • Alliance Manager Each Party shall appoint a person(s) who shall oversee contact between the Parties for all matters between meetings of each Joint Committee and shall have such other responsibilities as the Parties may agree in writing after the Effective Date (each, an “Alliance Manager”). Each Party may replace its Alliance Manager at any time by notice in writing to the other Party.

  • Alliance Managers In addition to the foregoing governance provisions, each of the Parties shall appoint a single individual to serve as that Party’s alliance manager (“Alliance Manager”). The role of each Alliance Manager will be to participate and otherwise facilitate the relationship between the Parties as established by this Agreement. A Party may replace its Alliance Manager from time to time upon written notice to the other Party.

  • Joint Commercialization Committee As of the Effective Date, the Parties have established a joint commercialization committee (the “Joint Commercialization Committee” or the “JCC”), composed of up to [ * ] representatives of each Party, to monitor and discuss the Commercialization of Products at the operational level. Each JCC representative shall have knowledge and expertise in the commercialization of products similar to Products. The JCC shall in particular:

  • Management Team Subject to any approval or consulting rights of the --------------- Joint Operations Committee, Manager shall engage or designate one or more individuals experienced in dental group management and direction, including, but not limited to, an administrator, who will be responsible for the overall administration of the Practice including day-to-day operations and strategic development activities.

  • Commercialization Plans As soon as practicable after formation of the JCC (following Acucela’s exercise of an Opt-In Right under Section 3.1), the JCC shall prepare and approve the initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation (and, if applicable, any New Formulation or Other Indication Product) in the Territory. The Parties shall use Commercially Reasonable Efforts to ensure that such initial Commercialization Plan for Commercialization of the Licensed Product for the Initial Indication in the Initial Formulation is consistent with the general Commercialization Plan outline set forth in Exhibit C attached hereto and incorporated herein (the “General Commercialization Plan Outline”). The JCC shall prepare and approve a separate Commercialization Plan for Commercialization of Licensed Product for the Initial Indication in the Initial Formulation in the Territory and for Commercialization of each Other Indication Product and New Formulation (if any) in the Territory, and shall update and amend each Commercialization Plan not less than annually or more frequently as needed to take into account changed circumstances or completion, commencement or cessation of Commercialization activities not contemplated by the then-current Commercialization Plan. Amendments and revisions to the Commercialization Plan shall be reviewed and discussed, in advance, by the JCC, and Otsuka agrees to consider proposals and suggestions made by Acucela regarding amendments and revisions to the Commercialization Plan. Any amendment or revision to the Commercialization Plan that provides for an increase or decrease in the number of FTEs for any Phase 3b Clinical Trials or Post-Approval Studies as compared to the previous version of the Commercialization Plan, or that provides for addition or discontinuation of tasks or activities as compared to the previous version of the Commercialization Plan, or that moves forward the timetable for activities reflected in the Commercialization Plan, shall provide for a reasonable ramp-up or wind-down period, as applicable, to accommodate a smooth and orderly transition of Commercialization activities to the amended or revised Commercialization Plan. Each Commercialization Plan shall identify the goals of Commercialization contemplated thereunder and shall address Commercialization (including Co-Promotion) activities related to the Licensed Product (including, if applicable, any Other Indication Product), including:

  • Development Plans 4.3.1 For each Licensed Indication and corresponding Licensed Product in the Field, Licensee will prepare and deliver to Licensor a development plan and budget (each a “Development Plan”). The initial Development Plans for each Licensed Indication will be delivered within […***…] after the Grant Date for such Licensed Indication.

  • Transition Plan 1. A transition plan is a detailed description of the process of transferring enrollees from non-participating providers to the Health Plan's behavioral health care provider network to ensure optimal continuity of care. The transition plan shall include, but not be limited to, a timeline for transferring enrollees, description of provider clinical record transfers, scheduling of appointments, and proposed prescription drug protocols and claims approval for existing providers during the transition period. The Health Plan shall document its efforts relating to the transition plan in the enrollee’s clinical records.

  • Development Plan As defined in Section 3.2(a).

Time is Money Join Law Insider Premium to draft better contracts faster.